Kolexia
Nachury Maria Gastro-entérologie
Nachury Maria
Gastro-entérologie
Hôpital Huriez
Lille, France
188 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Crohn Maladies inflammatoires intestinales Rectocolite hémorragique Colite Ulcère Nécrose Fistule rectale Obésité Fistule

Collaborateurs

Voir plus
Fumery Mathurin
Fumery Mathurin
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France
Peyrin-Biroulet Laurent
Peyrin-Biroulet Laurent
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Laharie David
Laharie David
Hôpital Haut-lévêque, Pessac, France
Buisson Anthony
Buisson Anthony
Hôpital Estaing, Clermont-Ferrand, France

Industries

Voir plus
Janssen
64 collaboration(s)
Dernière en 2023
Abbvie
58 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
19 collaboration(s)
Dernière en 2023
B3TSI
15 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
LUCENT-URGE: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Essai Clinique (Lilly)   07 mars 2024
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Essai Clinique (Takeda Pharmaceutical)   20 février 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   27 janvier 2024
ABTECT - Maintenance: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
Évaluation de la fréquence d’association des maladies inflammatoires dysimmunitaires (spondyloarthrite, psoriasis ou maladies inflammatoires chroniques de l’intestin) au CHU de Lille
36e Congrès Français de Rhumatologie   01 décembre 2023
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
Alimentary pharmacology & therapeutics   30 novembre 2023
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
Essai Clinique (CHU Rennes)   20 novembre 2023
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID.
Journal of Crohn's & colitis   20 octobre 2023
Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID.
Journal of Crohn's & colitis   05 octobre 2023